Study of daratumumab with teclistamab or talquetamab for frail patients with newly diagnosed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are newly diagnosed with multiple myeloma (have not had any treatment for it yet).
- Your disease is considered 'measurable' (has a certain level of protein in your blood or urine that can be tracked).
- You are considered frail based on a standard frailty score for myeloma patients.
- You have adequate kidney, liver, and blood cell counts as shown by lab tests.
- If you could become pregnant, you must agree to use highly effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs for patients with newly diagnosed, high-risk multiple myeloma. The goal is to see if this multi-target approach can improve outcomes by using the immune system to attack the cancer.
This study tests whether a combination of two new antibody drugs (teclistamab and talquetamab) works better than the standard combination (daratumumab and lenalidomide) for patients who still have minimal myeloma left after a stem cell transplant. The goal is to see if the new treatment can completely eliminate the remaining cancer cells and improve long-term outcomes.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.